The tobacco industry giant, Altria Group, has experienced a stretch of fluctuating stock performance in recent years. While traders have welcomed periods of upward movement, the firm's outlook remain a topic of discussion. Factors influencing Altria Group's stock comprise governmental actions, consumer trends, and the overall health of the tobacco

The landscape of diabetes management is continually evolving, bringing innovative therapies that offer improved efficacy and patient experience. Among these advancements, tirzepatide has emerged as a promising treatment option, demonstrating remarkable results in clinical trials. As a dual GLP-1 and GIP receptor agonist, tirzepatide modulates both